Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib
80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and
stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary
endpoint is the disease-free survival rate at 3 years.